Filing Details
CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) filed a Form 8-K with the Securities and Exchange Commission on July 15, 2026, disclosing a material event.
8k filedNASDAQ:CBIO
CRESCENT BIOPHARMA, INC. (CBIO) Reports Material Event to SEC
Filing Details CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) filed a Form 8-K with the Securities and Exchange Commission on July 15, 2026, disclosing a material event. Market Context…
Market Context
CRESCENT BIOPHARMA, INC.'s stock currently trades at $15.67 with a market capitalization of $213.7M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for CRESCENT BIOPHARMA, INC.'s stock.
All SEC filings for CRESCENT BIOPHARMA, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CBIO Stock Page
Frequently Asked Questions
Where can I read CBIO's SEC filings?
Browse all filings on our CBIO SEC filings page.
What types of SEC filings does CRESCENT BIOPHARMA, INC. file?
Public companies like CRESCENT BIOPHARMA, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.